Pinchuk T V, Fedulaev Yu N, Khairetdinova G A, Denisova N N, Chura O V, Logunova I Yu
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia,
Bull Exp Biol Med. 2014 Sep;157(5):552-4. doi: 10.1007/s10517-014-2612-z. Epub 2014 Sep 27.
Proinflammatory markers were evaluated in patients with chronic heart failure of ischemic origin and essential hypertension with preserved left-ventricular ejection fraction before and after a 6-month course of simvastatin therapy (20 mg/day). The study was carried out in 125 patients with diastolic dysfunction manifested as impaired relaxation and pseudonormalization. The main group received standard therapy for chronic heart failure and simvastatin, controls received only standard therapy. In addition, the results in the main group were compared in patients with different types of left-ventricular diastolic dysfunction. Simvastatin therapy significantly reduced the levels of C-reactive protein and IL-6.
在接受辛伐他汀治疗（20毫克/天）6个月疗程前后，对缺血性起源的慢性心力衰竭和左心室射血分数保留的原发性高血压患者的促炎标志物进行了评估。该研究在125例表现为舒张功能障碍（表现为舒张功能受损和假性正常化）的患者中进行。主要组接受慢性心力衰竭的标准治疗和辛伐他汀，对照组仅接受标准治疗。此外，还比较了主要组中不同类型左心室舒张功能障碍患者的结果。辛伐他汀治疗显著降低了C反应蛋白和IL-6的水平。
